GUGLIELMELLI, PAOLA
GUGLIELMELLI, PAOLA
Medicina Sperimentale e Clinica
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease
2020 Loscocco G.G.; Mannelli F.; Mannelli L.; Vergoni F.; Gesullo F.; Rotunno G.; Guglielmelli P.; Vannucchi A.M.
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis
2017 Passamonti, F.; Giorgino, T.; Mora, B.; Guglielmelli, P.; Rumi, E.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J. J.; Cervantes, F.; Devos, T.; Palandri, F.; De Stefano, V.; Ruggeri, M.; Silver, R. T.; Benevolo, G.; Albano, F.; Caramazza, D.; Merli, M.; Pietra, D.; Casalone, R.; Rotunno, G.; Barbui, T.; Cazzola, M.; Vannucchi, A. M.
A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells
2016 Calura, E; Pizzini, S; Bisognin, A; Coppe, A; Sales, G; Gaffo, E; Fanelli, T; Mannarelli, C; Zini, R; Norfo, R; Pennucci, V; Manfredini, R; Romualdi, C; Guglielmelli, P; Vannucchi, A M; Bortoluzzi, S
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
2010 Passamonti F; Cervantes F; Vannucchi AM; Morra E; Rumi E; Pereira A; Guglielmelli P; Pungolino E; Caramella M; Maffioli M; Pascutto C; Lazzarino M; Cazzola M; Tefferi A.
A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count
2023 Tefferi, Ayalew; Loscocco, Giuseppe G; Farrukh, Faiqa; Szuber, Natasha; Mannelli, Francesco; Pardanani, Animesh; Hanson, Curtis A; Ketterling, Rhett P; De Stefano, Valerio; Carobbio, Alessandra; Barbui, Tiziano; Guglielmelli, Paola; Gangat, Naseema; Vannucchi, Alessandro M
A life-threatening ruxolitinib discontinuation syndrome
2017 Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Pacilli, Annalisa; Bosi, Alberto; Vannucchi, Alessandro Maria
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
2020 Alessandra Carobbio, Paola Guglielmelli, Elisa Rumi, Chiara Cavalloni, Valerio De Stefano, Silvia Betti, Alessandro Rambaldi, Maria Chiara Finazzi, Juergen Thiele, Alessandro M. Vannucchi, Ayalew Tefferi,Tiziano Barbui
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.
2014 Verstovsek S;Passamonti F;Rambaldi A;Barosi G;Rosen PJ;Rumi E;Gattoni E;Pieri L;Guglielmelli P;Elena C;He S;Contel N;Mookerjee B;Sandor V;Cazzola M;Kantarjian HM;Barbui T;Vannucchi AM
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms.
2010 Rambaldi A; Dellacasa CM; Finazzi G; Carobbio A; Ferrari ML; Guglielmelli P; Gattoni E; Salmoiraghi S; Finazzi MC; Di Tollo S; D'Urzo C; Vannucchi AM; Barosi G; Barbui T.
A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS
2006 A. VANNUCCHI; A. PANCRAZZI; C. BOGANI; E. ANTONIOLI; P. GUGLIELMELLI
A safety evaluation of ruxolitinib for the treatment of polycythemia vera
2024 Boldrini, Valentina; Vannucchi, Alessandro M.; Guglielmelli, Paola
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.
2008 Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.
2014 Pennucci V;Zini R;Norfo R;Guglielmelli P;Bianchi E;Salati S;Sacchi G;Prudente Z;Tenedini E;Ruberti S;Paoli C;Fanelli T;Mannarelli C;Tagliafico E;Ferrari S;Vannucchi AM;Manfredini R.
Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations.
2015 Pennucci, V1; Zini, R; Norfo, R; Guglielmelli, Paola; Bianchi, E; Salati, S; Sacchi, G; Prudente, Z; Tenedini, E; Ruberti, S; Paoli, C; Fanelli, Tiziana; Mannarelli, C; Tagliafico, E; Ferrari, S; Vannucchi, Am; Manfredini, R; Bogani, C; Bosi, Alberto; Fanelli, T; Fjerza, Rajmonda; Guglielmelli, P.
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis.
2005 A. M. Vannucchi;A. Pancrazzi;P. Guglielmelli;S. D. Lollo;C. Bogani;G. Baroni;L. Bianchi;A. R. Migliaccio;A. Bosi;F. Paoletti
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms.
2013 Rumi E;Pietra D;Guglielmelli P;Bordoni R;Casetti I;Milanesi C;Sant'Antonio E;Ferretti V;Pancrazzi A;Rotunno G;Severgnini M;Pietrelli A;Astori C;Fugazza E;Pascutto C;Boveri E;Passamonti F;De Bellis G;Vannucchi A;Cazzola M.
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs
2021 Balliu M.; Calabresi L.; Bartalucci N.; Romagnoli S.; Maggi L.; Manfredini R.; Lulli M.; Guglielmelli P.; Vannucchi A.M.
Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances
2023 Vannucchi, Alessandro Maria; Guglielmelli, Paola
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI)
2022 Guglielmelli, Paola; Palandri, Francesca; Selleri, Carmine; Cilloni, Daniela; Mendicino, Francesco; Mazza, Patrizio; Pastore, Domenico; Palumbo, Giuseppe A; Santoro, Marco; Pavone, Vincenzo; Impera, Stefana; Morelli, Mara; Coco, Paola; Valsecchi, Diletta; Passamonti, Francesco; Breccia, Massimo
Advances in understanding and management of myeloproliferative neoplasms
2009 A.M. Vannucchi; P. Guglielmelli; A. Tefferi
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease | 2020 | Loscocco G.G.; Mannelli F.; Mannelli L.; Vergoni F.; Gesullo F.; Rotunno G.; Guglielmelli P.; Vannucchi A.M. | |
| A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis | 2017 | Passamonti, F.; Giorgino, T.; Mora, B.; Guglielmelli, P.; Rumi, E.; Maffioli, M.; Rambaldi, A.; Caramella, M.; Komrokji, R.; Gotlib, J.; Kiladjian, J. J.; Cervantes, F.; Devos, T.; Palandri, F.; De Stefano, V.; Ruggeri, M.; Silver, R. T.; Benevolo, G.; Albano, F.; Caramazza, D.; Merli, M.; Pietra, D.; Casalone, R.; Rotunno, G.; Barbui, T.; Cazzola, M.; Vannucchi, A. M. | |
| A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells | 2016 | Calura, E; Pizzini, S; Bisognin, A; Coppe, A; Sales, G; Gaffo, E; Fanelli, T; Mannarelli, C; Zini, R; Norfo, R; Pennucci, V; Manfredini, R; Romualdi, C; Guglielmelli, P; Vannucchi, A M; Bortoluzzi, S | |
| A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). | 2010 | Passamonti F; Cervantes F; Vannucchi AM; Morra E; Rumi E; Pereira A; Guglielmelli P; Pungolino E; Caramella M; Maffioli M; Pascutto C; Lazzarino M; Cazzola M; Tefferi A. | |
| A globally applicable "triple A" risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count | 2023 | Tefferi, Ayalew; Loscocco, Giuseppe G; Farrukh, Faiqa; Szuber, Natasha; Mannelli, Francesco; Pardanani, Animesh; Hanson, Curtis A; Ketterling, Rhett P; De Stefano, Valerio; Carobbio, Alessandra; Barbui, Tiziano; Guglielmelli, Paola; Gangat, Naseema; Vannucchi, Alessandro M | |
| A life-threatening ruxolitinib discontinuation syndrome | 2017 | Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Pacilli, Annalisa; Bosi, Alberto; Vannucchi, Alessandro Maria | |
| A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis | 2020 | Alessandra Carobbio, Paola Guglielmelli, Elisa Rumi, Chiara Cavalloni, Valerio De Stefano, Silvia Betti, Alessandro Rambaldi, Maria Chiara Finazzi, Juergen Thiele, Alessandro M. Vannucchi, Ayalew Tefferi,Tiziano Barbui | |
| A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. | 2014 | Verstovsek S;Passamonti F;Rambaldi A;Barosi G;Rosen PJ;Rumi E;Gattoni E;Pieri L;Guglielmelli P;Elena C;He S;Contel N;Mookerjee B;Sandor V;Cazzola M;Kantarjian HM;Barbui T;Vannucchi AM | |
| A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. | 2010 | Rambaldi A; Dellacasa CM; Finazzi G; Carobbio A; Ferrari ML; Guglielmelli P; Gattoni E; Salmoiraghi S; Finazzi MC; Di Tollo S; D'Urzo C; Vannucchi AM; Barosi G; Barbui T. | |
| A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS | 2006 | A. VANNUCCHI; A. PANCRAZZI; C. BOGANI; E. ANTONIOLI; P. GUGLIELMELLI | |
| A safety evaluation of ruxolitinib for the treatment of polycythemia vera | 2024 | Boldrini, Valentina; Vannucchi, Alessandro M.; Guglielmelli, Paola | |
| A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. | 2008 | Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi | |
| Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. | 2014 | Pennucci V;Zini R;Norfo R;Guglielmelli P;Bianchi E;Salati S;Sacchi G;Prudente Z;Tenedini E;Ruberti S;Paoli C;Fanelli T;Mannarelli C;Tagliafico E;Ferrari S;Vannucchi AM;Manfredini R. | |
| Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. | 2015 | Pennucci, V1; Zini, R; Norfo, R; Guglielmelli, Paola; Bianchi, E; Salati, S; Sacchi, G; Prudente, Z; Tenedini, E; Ruberti, S; Paoli, C; Fanelli, Tiziana; Mannarelli, C; Tagliafico, E; Ferrari, S; Vannucchi, Am; Manfredini, R; Bogani, C; Bosi, Alberto; Fanelli, T; Fjerza, Rajmonda; Guglielmelli, P. | |
| Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. | 2005 | A. M. Vannucchi;A. Pancrazzi;P. Guglielmelli;S. D. Lollo;C. Bogani;G. Baroni;L. Bianchi;A. R. Migliaccio;A. Bosi;F. Paoletti | |
| Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. | 2013 | Rumi E;Pietra D;Guglielmelli P;Bordoni R;Casetti I;Milanesi C;Sant'Antonio E;Ferretti V;Pancrazzi A;Rotunno G;Severgnini M;Pietrelli A;Astori C;Fugazza E;Pascutto C;Boveri E;Passamonti F;De Bellis G;Vannucchi A;Cazzola M. | |
| Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs | 2021 | Balliu M.; Calabresi L.; Bartalucci N.; Romagnoli S.; Maggi L.; Manfredini R.; Lulli M.; Guglielmelli P.; Vannucchi A.M. | |
| Acute Myocardial Infarction and Chronic Myeloproliferative Neoplasms: Friend and Enemy, Depending on Circumstances | 2023 | Vannucchi, Alessandro Maria; Guglielmelli, Paola | |
| Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) | 2022 | Guglielmelli, Paola; Palandri, Francesca; Selleri, Carmine; Cilloni, Daniela; Mendicino, Francesco; Mazza, Patrizio; Pastore, Domenico; Palumbo, Giuseppe A; Santoro, Marco; Pavone, Vincenzo; Impera, Stefana; Morelli, Mara; Coco, Paola; Valsecchi, Diletta; Passamonti, Francesco; Breccia, Massimo | |
| Advances in understanding and management of myeloproliferative neoplasms | 2009 | A.M. Vannucchi; P. Guglielmelli; A. Tefferi |